PBM Reform Is Finally Law: What the 2026 Appropriations Act Means for Independent Pharmacy Reimbursement

Your pharmacy fills the same prescription as the chain across the street. Same drug, same NDC, same patient copay. But when the remittance advice arrives, you were paid $18 less — and the plan was billed as if you were paid the higher amount. The spread stayed with the middleman.

If that pattern sounds familiar, February 2026 changed the rules that allowed it. Congress included a sweeping package of pharmacy benefit manager reforms in the Consolidated Appropriations Act of 2026, signed February 3, and for the first time federal law draws hard lines around spread pricing, affiliation steering, and below-cost reimbursement for independent pharmacies. Most provisions phase in during 2028 and 2029 — which means the contracts you sign and the records you keep in 2027 will determine how much protection you actually get.

This guide breaks down what passed, when each piece takes effect, whether you qualify as an "essential retail pharmacy," and how to rebuild your books before the new transparency and audit rights go live.

What Actually Passed — and Why It Was Inside a Spending Bill​

The reforms are Title I of H.R. 7148, the Consolidated Appropriations Act, 2026, a $1.2 trillion funding package. Rather than a standalone health bill, Congress merged the substance of the long-pending PBM Reform Act of 2025 (H.R. 4317) and bipartisan Senate Finance Committee proposals into the must-pass appropriations vehicle. It passed the House 217-214 and cleared the Senate the following week, with more than $321 million earmarked for drug-cost transparency enforcement.

That vehicle matters because the reforms are already law — there is no second vote to watch for — and because regulators are funded to enforce them.

Pharmacy trade groups on both the chain and independent sides called it the most significant federal PBM reform in two decades, in part because it reaches beyond Medicare Part D into reporting duties for PBMs that serve private employer plans.

The Five Pillars Every Pharmacy Owner Should Understand​

The statute organizes around five enforceable pillars: contract access, compensation, transparency, accountability, and essential-pharmacy protections.

1. Health Plan Transparency Goes Semiannual​

Starting with plan years that begin in 2029, PBMs serving group health plans and health-insurance issuers must send the plan sponsor a detailed report at least every six months — quarterly if the sponsor asks. Each report must disclose, at the drug level:

• Net drug spending after rebates, fees, and alternative discounts
• Manufacturer-derived revenue (rebates, administrative fees, price-protection payments)
• Amounts reimbursed to pharmacies, broken out by dispensing channel (independent retail, chain retail, mail, specialty, and any affiliate channel)
• Whether benefit designs were structured to steer patients toward PBM-affiliated pharmacies

Plan participants and beneficiaries get a summarized version each year and can request claim-level pricing for their own prescriptions — what the PBM paid the pharmacy versus what the plan was charged.

For employer-plan clients who are also your patients, this is a quiet lever. When an employer sees the spread on its own claims, its incentive to demand pass-through contracting rises. Pharmacies that keep clean, NDC-level reconciliation records will be the ones employers want in network.

2. The Flat-Fee Mandate Ends Spread Pricing as a Business Model​

Effective January 1, 2028, a PBM contracting with a Medicare Part D sponsor — including Medicare Advantage prescription-drug plans — may not retain revenue from rebates, spread pricing, or volume-based incentives. The PBM may be paid only through bona fide service fees that meet all four statutory tests:

1. A flat dollar amount, not a percentage of drug price, rebate, or reimbursement
2. For services actually performed and itemized (claims processing, formulary development, utilization review)
3. Consistent with fair market value
4. Not contingent on drug price, formulary placement, or referral volume or value

A parallel pass-through rule requires the PBM to remit to the sponsor 100% of rebates, fees, and alternative discounts tied to utilization and to disclose any manufacturer contracts that create financial incentives. PBMs serving private group health plans face a similar remittance duty: all drug-spending-linked remuneration must be disclosed and passed through.

What spread looked like in practice helps explain why this matters for your ledger. A PBM might reimburse your pharmacy $42 for a generic, bill the plan $68 for the same claim, and retain the $26 spread plus a $9 manufacturer rebate. Under the new model, the PBM bills a $4 flat adjudication fee and passes the $9 rebate to the plan, which decides whether to share savings with members. Your reimbursement and the plan's cost finally reference the same transaction.

3. Part D Reporting and Audit Rights Get Teeth​

Beginning July 1, 2028, PBMs must submit annual reports to each Part D sponsor and to the Centers for Medicare & Medicaid Services (CMS) with drug-by-drug and aggregate data on manufacturer revenue, total gross drug spending, average pharmacy reimbursement by dispensing channel, wholesale acquisition cost, out-of-pocket spending, affiliate arrangements, and compensation paid to brokers who influenced the contract.

Sponsors may audit the PBM at least annually using an auditor of the sponsor's choice. The PBM must produce all necessary records, data, and contracts within six months of an audit notice and answer follow-ups within 30 days. CMS can impose substantial civil monetary penalties on Part D sponsors that fail to enforce these duties, and contracts must include an accountability clause that makes the PBM financially responsible for penalties triggered by its own noncompliance.

For private plans, equivalent leverage arrives through the semiannual reporting cycle and the sponsor's right to demand quarterly detail. Employers that exercise those rights will generate the paper trail that later supports pharmacy-level reimbursement disputes.

4. Any Willing Pharmacy Becomes Federal Law​

Federal law has long contained an any-willing-pharmacy principle, but enforcement was uneven because "reasonable and relevant" contract terms were never defined. The 2026 reforms fix that.

Effective January 1, 2029, every Part D sponsor must allow any retail pharmacy to participate in its network if the pharmacy accepts the sponsor's standard terms — and the Secretary of Health and Human Services (HHS) must define "reasonable and relevant" by April 2028. That rulemaking will set the federal floor for reimbursement, audit provisions, claims timeliness, and network adequacy. Expect a proposal in 2027 with a comment period where independent pharmacy data will matter.

Practically, a PBM will no longer be able to exclude your pharmacy by quoting a take-it-or-leave-it rate that no unaffiliated pharmacy could accept. If HHS sets the floor and you meet it, the network must take you. Preserve every contract version and amendment letter starting now — the 2029 compliance test will turn on the paper you can produce.

5. Essential Retail Pharmacy Protections and the New HHS List​

The law creates a formal essential retail pharmacy category — an unaffiliated pharmacy where access is scarce. You qualify if:

• You are not an affiliate of a PBM or plan sponsor (no common ownership or control), and
• You are located in one of these geographies:
  • A federally designated medically underserved area, or
  • A rural area with no other retail pharmacy within 10 miles
  • A suburban area with no other retail pharmacy within 2 miles
  • An urban area with no other retail pharmacy within 1 mile

HHS must publish the essential retail pharmacy list before each plan year and report to Congress every two years on network participation, reimbursement trends, and closure rates for essential pharmacies versus the broader market.

The designation does not guarantee a higher rate, but it flags you for enhanced network-adequacy monitoring, makes discriminatory reimbursement against unaffiliated pharmacies easier to prove, and gives employers and legislators a documented reason to question below-cost payment at an access-point pharmacy.

A confidential violation-reporting channel comes with both pillars. Pharmacies can report contract violations directly, sponsors are prohibited from retaliating against a pharmacy that files a report, and civil penalties for unreasonable terms begin in 2029 with the PBM contractually liable for penalties it caused.

When Each Piece Actually Takes Effect​

The staggered timeline is the biggest source of mistakes.

• Now through late 2027: No reimbursement floors change yet. Clean up reconciliation and track the HHS rulemaking on reasonable and relevant terms (due April 2028).
• January 1, 2028: Flat bona fide service fee model and full pass-through become mandatory for Part D PBM contracts. No retained spread or rebates on covered Part D drugs.
• July 1, 2028: First annual PBM-to-sponsor-and-CMS reports due. Sponsor audit rights become exercisable.
• January 1, 2029: Any willing pharmacy rule, essential retail pharmacy protections, and semiannual employer-plan reports take effect. HHS essential list is in force. Penalties for unreasonable terms begin.
• Ongoing: Biennial HHS reports on essential pharmacy reimbursement and participation.

If a PBM offers to "early adopt" a flat-fee amendment in 2027, read it against the four statutory tests. A fee labeled flat but still indexed to rebate volume or formulary tier fails and would need replacement in 2028.

What Changes in Your Books​

The law is written as a PBM reform but is experienced as a bookkeeping reform inside the pharmacy. Four workflows need rebuilding before 2028.

Rebuild the Revenue and Contra-Revenue Map​

Many independents still book a single "PBM remittance" deposit and let spread, retained rebates, and fees collapse into one net number. After the flat-fee shift, make the economics explicit:

• Gross prescription revenue — brand and generic, at adjudication, based on contracted ingredient cost plus dispensing fee, before variable consideration
• DIR and performance reserve (contra-revenue) — the ASC 606 estimate for post-sale adjustments; keep accruing it even after the 2024 point-of-sale DIR change, retuned to the last 12 months of actual performance adjustments by payer
• PBM service fee expense — the flat bona fide service fee the PBM charges the plan, tracked as an administrative fee rather than a reduction of your reimbursement, because it is not your cost
• Network and transaction fees — switch, claim, and access fees deducted from remittance, tracked separately from performance adjustments so an audit can distinguish adjudication cost from performance withhold

When average reimbursement per claim drops $2.50 in a month, a clean map lets you answer whether it was a MAC list change, a dispensing-fee cut, or a new per-claim deduction — the same three categories the annual reports will break out for sponsors.

Shift the Benchmark From MAC to NADAC​

Maximum Allowable Cost lists are proprietary PBM constructs. The National Average Drug Acquisition Cost (NADAC) is a survey of prices pharmacies actually paid, published weekly. State reforms in Montana, Connecticut, and Oregon already use NADAC-plus-dispensing-fee as a floor — typically 106% of NADAC plus $12 to $18 per prescription.

The federal reforms do not impose a NADAC floor, but they create the conditions for one: HHS must define reasonable and relevant terms and collect channel-breakout data that will make NADAC divergence visible. Pharmacies that track cost of goods at the NDC level against NADAC can document when a MAC fell below acquisition cost on the same claim where the plan was billed at NADAC-plus.

Add a weekly NADAC import to your pharmacy management system and subledger. Reconcile wholesaler invoices from your primary distributor against NADAC for the top 50 generics by volume each month. Flag variances over 5% for two consecutive weeks and preserve the NADAC snapshot.

Retire the DIR Reserve Slowly — Don't Zero It​

CMS required all pharmacy price concessions to move to point of sale on January 1, 2024. That cut the massive fourth-quarter clawbacks of the "DIR hangover" period, but it did not end variable consideration. PBMs still use performance-based adjustments tied to adherence and generic dispensing, some still deducted from future remittances.

Keep a DIR/performance reserve on the balance sheet, but recalibrate the rate using the last 12 months of actual adjustments by payer. Release the reserve as adjustments are known and true up quarterly with a disclosed change in estimate. Auditors will expect monthly accrual activity, not a single year-end entry.

For 340B contract pharmacy activity, keep inventory and revenue fully segregated. HRSA audited 115 covered entities in fiscal year 2025 and found adverse findings in 49%, most tied to contract pharmacy records, duplicate discounts, or diversion. Separate accounts for 340B-owned inventory are the cheapest audit insurance you can buy.

Prepare for Audit — Both Directions​

Two audit streams converge on the same records.

You audit the PBM: sponsors can demand records within six months and you can file a confidential violation report for discriminatory reimbursement or retaliation. The PBM audits you: it will test whether you billed at the rate you were reimbursed or at an inflated billed amount.

Preserve every adjudication response and remittance advice linked by claim ID, every MAC schedule with its effective date, every contract and amendment, and every communication that references pharmacy channel or steering.

A monthly close that survives either direction:

1. Tie adjudicated AR to the aging — every unpaid claim has a claim ID and payer.
2. Post each remittance file to the matching adjudicated receivable, with variances coded to MAC variance, transaction fee, or performance adjustment — not to cash.
3. Accrue the performance reserve as contra-revenue at the updated payer-specific rate.
4. Accrue expected prime-vendor rebates monthly as a reduction of cost of goods sold, releasing the accrual when the check arrives so margin matches the dispensing period.
5. Cycle-count high-value and high-velocity NDCs monthly, with a full physical at year-end, and post shrinkage to its own expense account.
6. Export and preserve a NADAC snapshot and a MAC snapshot on the last business day of the month.

Are You an Essential Retail Pharmacy? A Quick Self-Test​

Use this before the first HHS list publishes. If you answer yes to all three, prepare your packet.

1. Are you unaffiliated? No common ownership or control with a PBM or plan sponsor.

2. Are you geographically isolated or in a shortage area? Check HRSA's medically underserved area map — a designated tract qualifies regardless of distance. Otherwise, measure road distance to the next retail pharmacy: more than 10 miles in a rural tract, 2 miles in a suburban tract, or 1 mile in an urban tract qualifies. Document drive time and seasonal barriers — HHS will use access-based determinations, not just straight-line distance.

3. Can you prove it? Save the HRSA designation screenshot, a dated map, and your license showing no affiliate ownership. If HHS omits you, you will have the packet ready to request inclusion or support an employer's adequacy challenge.

Tag essential status in your payer master file so you can run reimbursement comparisons when the biennial HHS reports appear, and keep a one-page closure-risk memo — volume, distance to the next pharmacy, and share of patients who fill only with you. That is the document legislators ask for when a closure is announced, and it is harder to build under pressure.

A Six-Month Action Checklist​

This quarter:

• Inventory every PBM and PSAO contract version, including amendments and fee schedules. Missing amendments are the most common reason a reasonable-and-relevant challenge fails.
• Build or fix the three-account reconciliation: adjudicated AR, remittance-posted AR, and variance accounts.

Next quarter:

• Add NADAC to the monthly close and start preserving snapshots.
• Retune the performance reserve rate using the last 12 months of actual adjustments by payer.

Before April 2028:

• Comment on the HHS reasonable-and-relevant proposed rule. A two-paragraph letter attaching your MAC-versus-NADAC data for one payer carries more weight than a form letter.
• Ask each PSAO what the PBM's bona fide service fee schedule will be in 2028 and whether any current fee is still indexed to rebate or volume — get the answer in writing.

Across all quarters, keep employer relationships warm. An employer that understands its PBM's economics is more likely to choose pass-through contracts with explicit pharmacy networks, and a pharmacy with a reconciled, NADAC-anchored cost structure is an attractive participant for a self-insured employer shopping its PBM contract.

Mistakes That Will Cost More Under the New Rules​

• Booking deposits as revenue. You understate gross sales and bury deductible fees. Gross revenue is the adjudicated amount; the deposit is net after deductions.
• Burying the PBM service fee in contra-revenue. It is the plan's administrative expense. Hiding it in your revenue line makes your margin look worse than it is.
• Zeroing the performance reserve in 2028. The law bans retained spread and rebates, not performance adjustments. Keep a reserve until 12 months of post-reform data justify a new rate.
• Letting MAC updates overwrite history. Preserve each MAC version with effective dates — without versioned history you cannot prove a claim was paid under a MAC below NADAC on the dispense date.
• Commingling 340B inventory. Even one 340B vial counted as owned inventory can trigger a duplicate-discount finding. Use physical segregation and separate accounts.

Building a Ledger That Proves Fair Treatment​

The throughline of the 2026 reforms is not that every independent pharmacy gets paid more automatically — it is that the gap between what a plan pays and what a pharmacy receives finally has to be disclosed, disaggregated, and justified at fair market value. A pharmacy whose books can already answer that question claim by claim, NDC by NDC, does not just survive an audit. It wins network contracts, keeps employers in its corner, and closes the information asymmetry that made spread pricing profitable.

You have a window that prior attempts never offered: law is final, effective dates are known, and the data you collect now becomes the baseline HHS will use to judge whether the market actually changed. Treat the next two monthly closes as training for the 2028 reporting cycle. By the time the first bona fide service fee invoices and semiannual plan reports are due, the pharmacies with disciplined, version-controlled, NDC-level records will be the ones whose economics are easiest to defend — and to improve.

Simplify Your Financial Management​

As you prepare for new reimbursement rules and the documentation they demand, clear financial records are your strongest protection and your best negotiating tool. Beancount.io offers plain-text accounting that keeps every prescription claim, wholesaler invoice, and PBM remittance fully transparent, version-controlled, and ready for audit — no black boxes, no vendor lock-in. Get started for free and see why pharmacy owners and finance professionals are switching to plain-text accounting for complete control over their books.